GRK6 (G protein-coupled receptor kinase 6) is a serine/threonine kinase that phosphorylates activated G protein-coupled receptors (GPCRs), initiating β-arrestin-mediated receptor desensitization and internalization 1. The enzyme localizes to the plasma membrane and cytoplasm, where it regulates GPCR signaling pathway termination through phosphorylation of agonist-occupied receptors 2. GRK6 contains an AGC kinase domain, though hypoxia can promote expression of truncated isoforms lacking this domain 3. Post-translational palmitoylation of GRK6 is critical for its membrane translocation and activation of downstream signaling cascades. In triple-negative breast cancer (TNBC), GRK6 upregulation correlates with increased metastatic potential through activation of the β-Arrestin 2/MAPK/NF-κB axis, and GRK6 inhibition suppresses migration 1. Conversely, in lung adenocarcinoma, GRK6 is downregulated through promoter hypermethylation, with reduced expression promoting cell migration and invasion via altered E-cadherin/vimentin expression and increased matrix metalloproteinases 4. In pulmonary arterial hypertension, GRK6 overexpression provides protective effects by attenuating smooth muscle cell proliferation through STAT3 pathway inhibition 5. In inflammatory responses, GRK6 palmitoylation-dependent membrane translocation promotes PI3K/AKT signaling and inflammatory mediator release 6. These findings demonstrate context-dependent roles for GRK6 in cancer progression, cardiovascular disease, and inflammation.